Monsanto seeks Brazilian approval to test controversial weed-controlling dicamba herbicide-resistant GMO soy seeds

USDA Brazil soy crop production exports boosted

The Brazilian unit of seed and agrochemicals maker Monsanto on Thursday [Jan. 11] said it will run field tests with genetically modified soy seed INTACTA2 XTEND in Brazil in the 2019-20 crop, looking to launch the variety commercially the following year.

INTACTA2 XTEND seeds have been engineered to resist some weed killers, including those containing a chemical called dicamba. The use of dicamba-based products caused controversy in the United States last year with accusations that the product drifted and damaged neighboring crops.

“This new technology will boost weed control, particularly of some weed varieties that are resistant to glyphosate,” the company said.

Brazilian regulators approved late in 2016 a request from Monsanto to sell the dicamba-resistant seeds, but the company had declined to release plans to market the product in the country until now.

Brazil is the second-largest soybean producer after the United States and produced a record crop of 114.1 million tonnes last year. It is the world’s top exporter of the oilseed.

Read full, original post: Monsanto looking to sell dicamba-resistant GM soy seed in Brazil

{{ reviewsTotal }}{{ options.labels.singularReviewCountLabel }}
{{ reviewsTotal }}{{ options.labels.pluralReviewCountLabel }}
{{ options.labels.newReviewButton }}
{{ userData.canReview.message }}

Related Articles

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Does glyphosate—the world's most heavily-used herbicide—pose serious harm to humans? Is it carcinogenic? Those issues are of both legal and ...

Most Popular

Screenshot-2026-04-22-at-12.21.32-PM
Viewpoint: Why the retracted Monsanto glyphosate study doesn’t change the science—the world’s most popular herbicide is safe 
ChatGPT-Image-Apr-16-2026-02_56_53-PM
Financial incentives, over diagnosis, and weak oversight: Autism claims are driving up Medicare costs
Picture1
The FDA couldn’t find a vaccine safety crisis, so it buried its own research
ChatGPT-Image-May-1-2026-11_42_59-AM-2
Viewpoint: NAD is the wellness grifters latest evidence-lite longevity fad. At least the mice are impressed.
global warming
‘Implausible’: Top climate scientists reject worst-case scenario—soaring temperatures and fast-rising sea levels
Screenshot-2026-05-21-at-12.15.17-PM
UK gene-editing milestone: Livestock barley that increases ruminant value and reduces methane emissions is first-approved CRISPR crop

Sorry. No data so far.

glp menu logo outlined

Get news on human & agricultural genetics and biotechnology delivered to your inbox.